EE200000535A - Triasendatud 1,3,5-triasiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutami - Google Patents

Triasendatud 1,3,5-triasiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutami

Info

Publication number: EE200000535A
Authority: EE; Estonia
Prior art keywords: compound; preparation; trisubstituted; medicament; treatment
Prior art date: 1998-03-27

Application number

EEP200000535A

Other languages

English (en)

Estonian (et)

Inventor

Adriaan Jan Janssen Paul

Joseph Kukla Michael

Frans Desir Daeyaert Frederik

De Corte Bart

Ren De Jonge Marc

Heeres Jan

Yung Ho Chih

W. Kavash Robert

Maria Henricus Koymans Lucien

William Ludovici Donald

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-27

Filing date

1999-03-24

Publication date

2002-04-15

1999-03-24 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

2002-04-15 Publication of EE200000535A publication Critical patent/EE200000535A/xx

Links

150000001875 compounds Chemical class 0.000 title 2
125000003363 1,3,5-triazinyl group Chemical class N1=C(N=CN=C1)* 0.000 title 1
208000031886 HIV Infections Diseases 0.000 title 1
208000037357 HIV infectious disease Diseases 0.000 title 1
239000003814 drug Substances 0.000 title 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EEP200000535A 1998-03-27 1999-03-24 Triasendatud 1,3,5-triasiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutami EE200000535A (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7963398P	1998-03-27	1998-03-27
EP98201589A EP0945447A1 (en)	1998-03-27	1998-05-14	Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
PCT/EP1999/002044 WO1999050256A1 (en)	1998-03-27	1999-03-24	Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections

Publications (1)

Publication Number	Publication Date
EE200000535A true EE200000535A (et)	2002-04-15

Family

ID=22151790

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000535A EE200000535A (et)	1998-03-27	1999-03-24	Triasendatud 1,3,5-triasiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutami

Country Status (32)

Country	Link
US (3)	US6150360A (pl)
EP (2)	EP0945447A1 (pl)
JP (1)	JP2002511390A (pl)
KR (1)	KR100593396B1 (pl)
CN (1)	CN1157386C (pl)
AP (1)	AP1475A (pl)
AR (1)	AR018169A1 (pl)
AT (1)	ATE295355T1 (pl)
AU (1)	AU758624C (pl)
BG (1)	BG64903B1 (pl)
BR (1)	BR9909197A (pl)
CA (1)	CA2324921C (pl)
DE (1)	DE69925256T2 (pl)
DK (1)	DK1066269T3 (pl)
EA (1)	EA004540B1 (pl)
EE (1)	EE200000535A (pl)
ES (1)	ES2243056T3 (pl)
HR (1)	HRP20000621A2 (pl)
HU (1)	HUP0101372A3 (pl)
ID (1)	ID26043A (pl)
IL (1)	IL138670A (pl)
NO (1)	NO317425B1 (pl)
NZ (1)	NZ506787A (pl)
OA (1)	OA11493A (pl)
PL (1)	PL194660B1 (pl)
PT (1)	PT1066269E (pl)
SI (1)	SI1066269T1 (pl)
SK (1)	SK14052000A3 (pl)
TR (1)	TR200002761T2 (pl)
TW (1)	TW570917B (pl)
WO (1)	WO1999050256A1 (pl)
ZA (1)	ZA200006042B (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200200763T2 (tr)	1999-09-24	2003-09-22	Janssen Pharmaceutica N.V.	Antiviral bileşimler
DE19945982A1 (de) *	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
US6645964B1 (en) *	1999-11-29	2003-11-11	Aventis Pharma S.A.	Chemical derivatives and their application as antitelomerase agent
US6906067B2 (en) *	1999-12-28	2005-06-14	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of TNF-α expression
US6943161B2 (en) *	1999-12-28	2005-09-13	Pharmacopela Drug Discovery, Inc.	Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) *	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
AU782948B2 (en)	2000-05-08	2005-09-15	Janssen Pharmaceutica N.V.	Prodrugs of HIV replication inhibiting pyrimidines
AU783981C (en)	2000-05-08	2007-05-03	Janssen Pharmaceutica N.V.	HIV replication inhibitors
US6858608B2 (en) *	2001-01-09	2005-02-22	Aventis Pharma S.A.	Chemical derivatives and their application as antitelomerase agents
US6887873B2 (en) *	2001-03-23	2005-05-03	Aventis Pharma S.A.	Triazine derivatives and their application as antitelomerase agents
US6958211B2 (en)	2001-08-08	2005-10-25	Tibotech Bvba	Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7163943B2 (en) *	2001-09-21	2007-01-16	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
US7112587B2 (en)	2001-09-21	2006-09-26	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
US7173032B2 (en) *	2001-09-21	2007-02-06	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
WO2003024926A2 (en) *	2001-09-21	2003-03-27	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
US7132423B2 (en) *	2001-09-21	2006-11-07	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
US7169785B2 (en) *	2001-09-21	2007-01-30	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
AU2002342018A1 (en) *	2001-10-12	2003-04-28	New York University	Trisubstituted triazines compounds with antitubulin activity
WO2003037346A1 (en) *	2001-10-31	2003-05-08	Cell Therapeutics, Inc.	6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
KR100875362B1 (ko) *	2002-02-05	2008-12-22	아스텔라스세이야쿠 가부시키가이샤	2,4,6-트리아미노-1,3,5-트리아진 유도체
AR039540A1 (es)	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
US7419984B2 (en) *	2002-10-17	2008-09-02	Cell Therapeutics, Inc.	Pyrimidines and uses thereof
US20070232572A1 (en) *	2003-02-07	2007-10-04	Aventis Pharma S.A.	Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
HRP20050690A2 (en) *	2003-02-07	2006-08-31	Janssen Pharmaceutica N.V.	Hiv inhibiting 1,2,4-triazines
CL2004000306A1 (es)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
US6875781B2 (en) *	2003-04-04	2005-04-05	Cell Therapeutics, Inc.	Pyridines and uses thereof
ES2667668T3 (es)	2003-07-17	2018-05-14	Janssen Sciences Ireland Uc	Procedimiento para preparar partículas que contienen un antiviral
WO2005009980A1 (en) *	2003-07-22	2005-02-03	Neurogen Corporation	Substituted pyridin-2-ylamine analogues
US7335770B2 (en) *	2004-03-24	2008-02-26	Reddy U5 Therapeutics, Inc.	Triazine compounds and their analogs, compositions, and methods
US7923554B2 (en)	2004-08-10	2011-04-12	Janssen Pharmaceutica N.V.	HIV inhibiting 1,2,4-triazin-6-one derivatives
ES2371924T3 (es)	2004-09-30	2012-01-11	Tibotec Pharmaceuticals	Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv.
JP5046943B2 (ja)	2004-09-30	2012-10-10	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害性５−置換ピリミジン
WO2006035067A2 (en)	2004-09-30	2006-04-06	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5-heterocyclyl pyrimidines
JP5118972B2 (ja)	2004-10-29	2013-01-16	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害性二環式ピリミジン誘導体
US7592451B2 (en) *	2005-06-23	2009-09-22	New York University	Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments
WO2007071199A1 (en) *	2005-12-22	2007-06-28	Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences	2,4-disubstituted amido-6-substituted-[1,3,5]triazine or 1,3-pyrimidine compounds, their processes for preparation, their pharmaceutical compositions and uses thereof
CN101405283B (zh)	2006-03-30	2014-06-18	泰博特克药品有限公司	Hiv抑制性5-酰氨基取代的嘧啶类化合物
AU2007341227C1 (en)	2006-12-29	2013-08-29	Janssen Sciences Ireland Uc	HIV inhibiting 6-substituted pyrimidines
AU2007341228B2 (en)	2006-12-29	2013-04-18	Janssen Sciences Ireland Uc	HIV inhibiting 5,6-substituted pyrimidines
JP6184866B2 (ja)	2010-10-27	2017-08-23	ウォルターアンドエリザホールインスティテュートオブメディカルリサーチ	新規抗がん剤
GB201119358D0 (en)	2011-11-10	2011-12-21	Lewi Paulus J	Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en)	2012-03-19	2012-05-02	Lewi Paulus J	Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2014072419A1 (en)	2012-11-08	2014-05-15	Universiteit Antwerpen	Novel anti-hiv compounds
US9914709B2 (en) *	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
EP3122736A1 (en) *	2014-03-28	2017-02-01	Basf Se	Diaminotriazine derivatives as herbicides
MX383072B (es)	2015-12-24	2025-03-13	Univ California	Reguladores del cftr y métodos para su uso
JP2020531511A (ja)	2017-08-24	2020-11-05	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	眼球用医薬組成物
CN109053613A (zh) *	2018-07-04	2018-12-21	复旦大学	含有联苯结构的二芳基三嗪类化合物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2742466A (en) *		1956-04-17		Chx n nhx c c
US2671810A (en) *	1952-05-24	1954-03-09	Du Pont	Long-chain diketones
BE754242A (fr) *	1970-07-15	1971-02-01	Geigy Ag J R	Diamino-s-triazines et dinitro-s-triazines
US4096206A (en)	1976-02-09	1978-06-20	Borg-Warner Corporation	Flame-retardant triazines
US4652645A (en)	1983-11-16	1987-03-24	Ciba-Geigy Corporation	Cationic compounds
EP0541966A3 (en) *	1991-11-15	1994-09-07	American Cyanamid Co	Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) *	1992-06-19	1994-02-01	Uniroyal Chemical Company, Inc.	Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
BR9407799A (pt)	1993-10-12	1997-05-06	Du Pont Merck Pharma	Composição de matéria método de tratamento e composição farmaceutica
GB9519197D0 (en) *	1995-09-20	1995-11-22	Affinity Chromatography Ltd	Novel affinity ligands and their use
CN1163401A (zh) *	1996-02-13	1997-10-29	李占元	全自动血球计数仪试剂及配制方法
WO1999036410A1 (en) *	1998-01-13	1999-07-22	Scriptgen Pharmaceuticals, Inc.	Triazine antiviral compounds

1998
- 1998-05-14 EP EP98201589A patent/EP0945447A1/en not_active Withdrawn
1999
- 1999-03-24 WO PCT/EP1999/002044 patent/WO1999050256A1/en not_active Ceased
- 1999-03-24 EA EA200000993A patent/EA004540B1/ru not_active IP Right Cessation
- 1999-03-24 SI SI9930807T patent/SI1066269T1/xx unknown
- 1999-03-24 DK DK99917863T patent/DK1066269T3/da active
- 1999-03-24 AT AT99917863T patent/ATE295355T1/de not_active IP Right Cessation
- 1999-03-24 EP EP99917863A patent/EP1066269B1/en not_active Expired - Lifetime
- 1999-03-24 BR BR9909197-6A patent/BR9909197A/pt not_active Application Discontinuation
- 1999-03-24 EE EEP200000535A patent/EE200000535A/xx unknown
- 1999-03-24 AP APAP/P/2000/001913A patent/AP1475A/en active
- 1999-03-24 PT PT99917863T patent/PT1066269E/pt unknown
- 1999-03-24 CN CNB998044474A patent/CN1157386C/zh not_active Expired - Fee Related
- 1999-03-24 KR KR1020007007971A patent/KR100593396B1/ko not_active Expired - Fee Related
- 1999-03-24 ID IDW20001895A patent/ID26043A/id unknown
- 1999-03-24 DE DE69925256T patent/DE69925256T2/de not_active Expired - Fee Related
- 1999-03-24 NZ NZ506787A patent/NZ506787A/xx unknown
- 1999-03-24 JP JP2000541160A patent/JP2002511390A/ja active Pending
- 1999-03-24 HR HR20000621A patent/HRP20000621A2/hr not_active Application Discontinuation
- 1999-03-24 PL PL99343195A patent/PL194660B1/pl not_active IP Right Cessation
- 1999-03-24 CA CA002324921A patent/CA2324921C/en not_active Expired - Fee Related
- 1999-03-24 ES ES99917863T patent/ES2243056T3/es not_active Expired - Lifetime
- 1999-03-24 SK SK1405-2000A patent/SK14052000A3/sk unknown
- 1999-03-24 AU AU35997/99A patent/AU758624C/en not_active Ceased
- 1999-03-24 TR TR2000/02761T patent/TR200002761T2/xx unknown
- 1999-03-24 HU HU0101372A patent/HUP0101372A3/hu unknown
- 1999-03-25 US US09/276,362 patent/US6150360A/en not_active Expired - Fee Related
- 1999-03-26 TW TW088104756A patent/TW570917B/zh not_active IP Right Cessation
- 1999-03-26 AR ARP990101363A patent/AR018169A1/es unknown
2000
- 2000-08-08 US US09/634,340 patent/US6372729B1/en not_active Expired - Fee Related
- 2000-08-28 BG BG104716A patent/BG64903B1/bg unknown
- 2000-09-25 IL IL13867000A patent/IL138670A/xx not_active IP Right Cessation
- 2000-09-26 NO NO20004809A patent/NO317425B1/no unknown
- 2000-09-27 OA OA1200000266A patent/OA11493A/en unknown
- 2000-10-26 ZA ZA200006042A patent/ZA200006042B/xx unknown
2002
- 2002-02-05 US US10/067,383 patent/US6774235B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1999050256A1 (en)	1999-10-07
PL194660B1 (pl)	2007-06-29
TW570917B (en)	2004-01-11
KR20010034270A (ko)	2001-04-25
US20020115668A1 (en)	2002-08-22
US6372729B1 (en)	2002-04-16
NZ506787A (en)	2003-02-28
AP2000001913A0 (en)	2000-09-30
CA2324921A1 (en)	1999-10-07
IL138670A (en)	2005-12-18
OA11493A (en)	2004-05-07
SK14052000A3 (sk)	2001-06-11
ATE295355T1 (de)	2005-05-15
DE69925256T2 (de)	2006-02-23
AU758624C (en)	2004-03-11
EA004540B1 (ru)	2004-06-24
US6150360A (en)	2000-11-21
HK1032394A1 (en)	2001-07-20
JP2002511390A (ja)	2002-04-16
DK1066269T3 (da)	2005-09-05
EP1066269A1 (en)	2001-01-10
ES2243056T3 (es)	2005-11-16
AU3599799A (en)	1999-10-18
AU758624B2 (en)	2003-03-27
CN1295566A (zh)	2001-05-16
CA2324921C (en)	2009-05-12
EP1066269B1 (en)	2005-05-11
HUP0101372A2 (hu)	2001-10-28
BR9909197A (pt)	2000-12-05
AP1475A (en)	2005-10-03
EA200000993A1 (ru)	2001-04-23
US6774235B2 (en)	2004-08-10
KR100593396B1 (ko)	2006-06-28
ZA200006042B (en)	2001-10-26
ID26043A (id)	2000-11-16
CN1157386C (zh)	2004-07-14
DE69925256D1 (de)	2005-06-16
HRP20000621A2 (en)	2001-04-30
TR200002761T2 (tr)	2001-01-22
AR018169A1 (es)	2001-10-31
BG104716A (en)	2001-04-30
PT1066269E (pt)	2005-09-30
EP0945447A1 (en)	1999-09-29
NO317425B1 (no)	2004-10-25
HUP0101372A3 (en)	2003-02-28
BG64903B1 (bg)	2006-08-31
SI1066269T1 (en)	2005-10-31
NO20004809D0 (no)	2000-09-26
PL343195A1 (en)	2001-07-30
NO20004809L (no)	2000-11-24

Publication	Publication Date	Title
EE200000535A (et)	2002-04-15	Triasendatud 1,3,5-triasiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutami
EE04850B1 (et)	2007-06-15	Pürimidiini derivaatide kasutamine ravimi valmistamiseks, mis on ette nähtud HIV nakkuse raviks, ühend, seda sisaldav farmatseutiline kompositsioon, meetod ühendi ja kompositsiooni valmistamiseks ning kombineeritud preparaat kasutamiseks HIV nakku
EE04962B1 (et)	2008-02-15	Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks
IL143512A (en)	2013-06-27	Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus
EE200200202A (et)	2003-06-16	Uudsed tritsüklilised ühendid, nende saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud HIV-nakkuse raviks, ning neid sisaldav farmatseutiline kompositsioon
EE200100495A (et)	2002-12-16	Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
EE9700253A (et)	1998-04-15	Asendatud diamino-1,3,5-triasiini derivaat , selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod ning ühendi kombinatsioon ja seda sisaldav toode
EE200000482A (et)	2002-02-15	Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
EE200000483A (et)	2002-02-15	Glütsiini ülekannet pärssiva ühendi kasutamine ravimi valmistamiseks, ühend, seda sisaldav kompositsioon ning meetod ühendi ja kompositsiooni valmistamiseks
MX9605741A (es)	1997-05-31	Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
NO308580B1 (no)	2000-10-02	Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin
NO305903B1 (no)	1999-08-16	Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
EE04493B1 (et)	2005-06-15	Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
HUP9802897A3 (en)	2001-08-28	Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EE03514B1 (et)	2001-10-15	Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
EE200100596A (et)	2003-02-17	Ülipuhas (1R,2S,4R)-(-)-2-[(2'-{N,N-dimetüülamino}etoksü)]-2-[fenüül]-1,7,7-tri[metüül]bitsüklo[2.2.1 ]heptaan ja selle farmatseutiliselt vastuvõetavad happeliitsoolad ning nimetatud ühendite, samutiravimite, mis sisaldavad üks või enam nimetatud üh
BR9102730A (pt)	1992-02-04	Derivados de aminoacidos, processo para a preparacao de um composto, medicamento, invencao e processo para o tratamento ou prevencao de pressao elevada
EE200200260A (et)	2003-06-16	Pürasolo[1,5-d][1,2,4]triasiinderivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni suurendamiseks, ning seda sisaldav farmatseutiline kompositsioon
FI950575A7 (fi)	1995-02-09	3- ja 5-substituoidut 1,2,3,4-oksatriatsoli-5-imiiniyhdisteet, niiden valmistusmenetelmä, mainittuja yhdisteitä sisältävä farmaseuttinen valmiste ja mainittujen yhdisteiden käyttö lääkkeiden valmistukseen
HUP0300313A3 (en)	2007-05-02	Compound, pharmaceutical composition containing it and its use for the treatment of pain
HUP9801596A3 (en)	2000-07-28	Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them
HUP9802896A3 (en)	2001-08-28	Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
IL138670A0 (en)	2001-10-31	Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
BR9104649A (pt)	1992-03-24	Composto quimico derivado de 4(1h)quinolona,composicao farmaceutica,processos para a preparacao de derivados de 4(1h)quinolona e para o tratamento de disturbios cardiovasculares ou respiratorios
TH33733A (th)	1999-07-09	ไตรเอโซโลฟิวรีนส์ชนิดใหม่ ขบวนการสำหรับการเตรียมสารเหล่านี้และการใช้ประโยชน์ในการเป็นผลิตภัณฑ์ยาของสารเหล่านี้